Loading...
Market
What will be KERENDIA®'s market share in the heart failure treatment market by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Industry reports and market analysis from firms like IMS Health or IQVIA
Story
Bayer's Finerenone Achieves Primary Endpoint in Phase III HFmrEF and HFpEF Study
Aug 5, 2024, 06:40 AM
Bayer has announced that its Phase III FINEARTS-HF cardiovascular outcomes study investigating KERENDIA® (finerenone) in patients with heart failure with mildly reduced or preserved ejection fraction has achieved its primary endpoint. The study showed that finerenone, a non-steroidal MRA, demonstrated definitive cardiovascular benefits in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF), including reductions in CVd+total HF events. The results are seen as key to unlocking blockbuster sales for the drug. Full results will be presented at the upcoming ESC Congress.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
